Validation of reference tissue model of PET ligand [ 11C](+)3-MPB for the muscarinic cholinergic receptor in the living brain of conscious monkey

Synapse

Volumn 65, Issue 6, 2011, Pages 548-551

  Yamamoto, Shigeyuki ^a   Ohba, Hiroyuki ^b   Nishiyama, Shingo ^b   Takahashi, Kazuhiro ^c   Tsukada, Hideo ^b  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b CENTRAL RESEARCH LABORATORY   (Japan)

^c RESEARCH INSTITUTE FOR BRAIN AND BLOOD VESSELS AKITA   (Japan)

Author keywords

11C (+)3 MPB; Logan arterial input method; Logan reference tissue method; Muscarinic cholinergic receptor; PET

Indexed keywords

MEPENZOLATE; MUSCARINIC RECEPTOR; N METHYL 3 PIPERIDYL BENZILATE CARBON 11; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTERIAL BLOOD; ARTICLE; BLOOD SAMPLING; CEREBELLUM; IN VIVO STUDY; MACACA MULATTA; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL;

ANIMALS; CARBON RADIOISOTOPES; CEREBELLUM; LIGANDS; LYSINE; MACACA MULATTA; MALEIMIDES; MODELS, MOLECULAR; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, MUSCARINIC;

EID: 79953288150     PISSN: 08874476     EISSN: 10982396     Source Type: Journal    
DOI: 10.1002/syn.20881     Document Type: Article

References (16)

1. Collerton D. 1986. Cholinergic function and intellectual decline in Alzheimer's disease. Neuroscience 19: 1-28.
2. Frey KA, Ehrenkaufer RL, Agranoff BW. 1985. Quantitative in vivo receptor binding. II. Autoradiographic imaging of muscarinic cholinergic receptors. J Neurosci 5: 2407-2414.
3. Frey KA, Howland MM. 1992. Quantitative autoradiography of muscarinic cholinergic receptor binding in the rat brain: Distinction of receptor subtypes in antagonist competition assays. J Pharmacol Exp Ther 263: 1391-1400.
4. Hasselmo ME, Stern CE. 2006. Mechanisms underlying working memory for novel information. Trends Cogn Sci 10: 487-493.
5. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, Holden J, Houle S, Huang SC, Ichise M, Iida H, Ito H, Kimura Y, Koeppe RA, Knudsen GM, Knuuti J, Lammertsma AA, Laruelle M, Logan J, Maguire RP, Mintun MA, Morris ED, Parsey R, Price JC, Slifstein M, Sossi V, Suhara T, Votaw JR, Wong DF, Carson RE. 2007. Consensus nomenclature for in vivo imaging ofreversibly binding radioligands. J Cereb Blood Flow Metab 27: 1533-1539.
6. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 10: 740-747.
7. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL. 1996. Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16: 834-840.
8. 18F]CPFPX: Displacement studies in humans. Neuroimage 32: 1100-1105.
9. 11)C]methyl-3-piperidyl benzilate in the conscious monkey brain. Synapse 40: 159-169.
10. 11C]PE2I and positron emission tomography: Evaluation of reference tissue models. Ann Nucl Med 24: 249-260.
11. Sellin AK, Shad M, Tamminga C. 2008. Muscarinic agonists for the treatment of cognition in schizophrenia. CNS Spectr 13: 985-996.
12. Takahashi K. 1998. Development and clinical application of novel C-11-labeled ligand for imaging cholinergic muscarinic receptors in the brain with positron emission tomography. Ph.D. Thesis, Tohoku University.
13. 11C]methyl-3-piperidyl benzilate as a potent radioligand for positron emission tomography. Appl Radiat Isot 50: 521-525.
14. 11)C]methyl-3-piperidyl benzilate in the brains of conscious monkeys. Synapse 41: 248-257.
15. 11C]4-MPB. Synapse 39: 182-192.
16. Watanabe M, Okada H, Shimizu K, Omura T, Yoshikawa E, Kosugi T, Mori S, Yamashita T. 1997. A high resolution animal PET scanner using compact PS-PMT detectors. IEEE Trans Nucl Sci 44: 1277-1282.